Peregrine Asset Advisers Inc. Purchases 13,173 Shares of Amgen Inc. $AMGN

Key Points

• Peregrine Asset Advisers boosted its stake in Amgen by 526.9% in Q4, acquiring 13,173 shares to hold 15,673 shares worth about $5.13 million, representing ~1.4% of the firm's holdings and Amgen's 25th largest position.
• Amgen beat Q1 estimates with $5.15 EPS and $8.62 billion revenue (revenue +5.8% y/y), and set FY‑2026 guidance of $21.70–$23.10 EPS, a range broadly in line with consensus (~22.28).
• Management announced a quarterly dividend of $2.52 per share (annualized $10.08, ~3.1% yield), while the stock faces mixed analyst views and risks including an FDA proposal to withdraw Tavneos approval and investor concerns over the company’s obesity strategy (MariTide).

Peregrine Asset Advisers Inc. boosted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 526.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 15,673 shares of the medical research company's stock after acquiring an additional 13,173 shares during the period. Amgen accounts for about 1.4% of Peregrine Asset Advisers Inc.'s holdings, making the stock its 25th biggest position. Peregrine Asset Advisers Inc.'s holdings in Amgen were worth $5,130,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. West Family Investments Inc. boosted its holdings in Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company's stock worth $779,000 after acquiring an additional 30 shares in the last quarter. Viawealth LLC lifted its holdings in shares of Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company's stock valued at $2,023,000 after purchasing an additional 30 shares in the last quarter. LOM Asset Management Ltd lifted its holdings in shares of Amgen by 1.2% in the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company's stock valued at $721,000 after purchasing an additional 30 shares in the last quarter. Smith Salley Wealth Management lifted its holdings in shares of Amgen by 0.3% in the fourth quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company's stock valued at $3,530,000 after purchasing an additional 30 shares in the last quarter. Finally, Evergreen Private Wealth LLC increased its position in shares of Amgen by 4.0% during the fourth quarter. Evergreen Private Wealth LLC now owns 785 shares of the medical research company's stock valued at $257,000 after acquiring an additional 30 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen's Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Stock Performance

AMGN opened at $329.82 on Monday. The business has a 50 day simple moving average of $358.07 and a two-hundred day simple moving average of $341.12. The firm has a market capitalization of $178.00 billion, a price-to-earnings ratio of 22.95, a PEG ratio of 3.24 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 0.90. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts predict that Amgen Inc. will post 22.28 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. Amgen's dividend payout ratio is 70.84%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent research reports. Jefferies Financial Group began coverage on Amgen in a research report on Tuesday, March 10th. They issued a "hold" rating and a $350.00 price target for the company. TD Cowen reaffirmed a "buy" rating on shares of Amgen in a research note on Wednesday, February 4th. Wells Fargo & Company lifted their price target on Amgen from $375.00 to $390.00 and gave the stock an "equal weight" rating in a research note on Thursday, March 19th. Sanford C. Bernstein lowered Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 target price for the company. in a research note on Tuesday, January 20th. Finally, Canaccord Genuity Group began coverage on Amgen in a research note on Monday, April 20th. They issued a "hold" rating and a $366.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Amgen presently has an average rating of "Hold" and a consensus target price of $357.54.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.